Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Zimlovisertib Modified Release in Healthy Japanese Adults
NCT02936154Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2016
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zimlovisertib in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) (2 arms), sponsored by Pfizer. Primary endpoint: Number of participants experiencing an AE/SAE at Day 18. Started Aug 2016; status: completed.
02
Drugs
zimlovisertib
03
Conditions
rheumatoid arthritis (RA)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02936154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02936154.